Non Alcoholic Steatohepatitis Clinical Trial
Official title:
The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of Flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 2 and 3 will be randomly allocated to receive placebos or 30 grams Flaxseed powder for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory markers, and liver fibrosis will be assessed and compared between groups.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
Completed |
NCT01695083 -
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
|
||
Not yet recruiting |
NCT05605158 -
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
|
Phase 3 | |
Completed |
NCT01761370 -
Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)
|
N/A | |
Completed |
NCT03432377 -
Coffee Consumption and NASH in the French Population.
|
||
Withdrawn |
NCT03864835 -
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
|
N/A | |
Completed |
NCT05357352 -
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
|
||
Not yet recruiting |
NCT03803540 -
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 1 | |
Completed |
NCT01791959 -
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05821010 -
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT03734510 -
The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study
|
N/A | |
Recruiting |
NCT02721264 -
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
|
N/A | |
Terminated |
NCT03883607 -
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03863574 -
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT03377153 -
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT03377140 -
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
Active, not recruiting |
NCT04669158 -
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06176079 -
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
|
||
Withdrawn |
NCT01384578 -
Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis
|
Phase 3 |